Heart Failure, Anticoagulation & Echo Interpretation In Primary Care With Midge Bowers

Diagnosing cardiovascular disease is only the beginning. Once you've made the diagnosis, how do you safely adjust heart failure medications? When should you worry about a rise in creatinine after starting an ACE inhibitor or SGLT2 inhibitor? How do you interpret an echocardiogram beyond the ejection fraction? And when is a DOAC a better choice than warfarin?

I’m excited to introduce you to an absolute gem in the field of healthcare—Midge Bowers, Clinical Professor and Director of the Cardiovascular Specialty at Duke University School of Nursing. She also actively practices as a nurse practitioner in a Heart Failure Access Clinic, with a unique blend of theoretical knowledge and hands-on experience.

In this conversation, we walk through the real-world decisions primary care clinicians make every day—from titrating heart failure medications and managing volume overload to interpreting echocardiograms, prescribing anticoagulation, and deciding what to do when kidney function changes after starting evidence-based therapy. Throughout the episode, we walk through the clinical reasoning behind these decisions so you can feel more confident managing cardiovascular disease between cardiology visits.

Editor's note: This episode was originally recorded before several recent cardiovascular guideline updates. The episode and accompanying show notes were clinically reviewed in July 2026. Updated guidance has been added below where recommendations have evolved or where additional clinical context is important, particularly for heart failure management, atrial fibrillation, anticoagulation, and periprocedural management of oral anticoagulants.

 

Listen

 
 

Watch

 
 

What You’ll Learn

In this episode, you’ll learn:

  • How to safely titrate heart failure medications in primary care

  • When changes in creatinine and kidney function are expected—and when they aren't

  • How to interpret echocardiogram findings beyond the ejection fraction

  • Practical pearls for choosing and adjusting anticoagulation

  • When to prescribe a DOAC versus warfarin

  • How to adjust warfarin safely using total weekly dosing

  • What clinicians should know before holding anticoagulation for procedures

  • How experienced cardiology clinicians approach medication decisions in real-world practice

Clinical Updates: Reviewed July 2026

The practical framework in this episode remains useful, particularly the discussion of multidisciplinary collaboration, the four foundational medication classes for HFrEF, and the importance of helping patients receive evidence-based therapy. Keep the following updates in mind when applying the episode to current practice.

Heart failure medication therapy

The four foundational medication classes for HFrEF remain:

  • a renin-angiotensin system inhibitor (preferably an ARNI when appropriate, with an ACE inhibitor or ARB used when ARNI therapy is not feasible),

  • an evidence-based beta blocker,

  • a mineralocorticoid receptor antagonist (MRA), and

  • an SGLT2 inhibitor.

SGLT2 inhibitors remain recommended regardless of diabetes status for appropriate patients with symptomatic HFrEF. Since this episode was recorded, evidence has also expanded the role of SGLT2 inhibitors in patients with HFmrEF and HFpEF, where they reduce heart failure hospitalizations and improve cardiovascular outcomes in appropriate patients. While these medications may have a modest diuretic effect, the loop diuretic dose does not automatically need to be reduced when an SGLT2 inhibitor is started. Any medication adjustment should be individualized based on the patient's volume status, blood pressure, kidney function, symptoms, and follow-up plan.

Kidney Function Monitoring

Serum creatinine should always be interpreted alongside eGFR, potassium, volume status, and the overall clinical picture. ACE inhibitors, ARBs, ARNIs, MRAs, SGLT2 inhibitors, and diuretics can all influence kidney-related laboratory values. A modest early rise in creatinine may be an expected physiologic response with some therapies, and laboratory changes should be interpreted in the context of the patient's underlying kidney disease, indication for treatment, and expected medication effects.

Echocardiogram Interpretation

Regional wall-motion abnormalities can increase suspicion for ischemic heart disease, but global hypokinesis does not, by itself, establish a nonischemic cardiomyopathy. Both ischemic and nonischemic conditions—multivessel coronary disease, prior diffuse ischemic injury, tachycardia-mediated cardiomyopathy, stress cardiomyopathy, myocarditis, toxic causes, and other conditions— can produce global dysfunction can cause global ventricular dysfunction, so echocardiographic findings should always be interpreted alongside the patient's history, clinical presentation, and additional diagnostic evaluation.

Atrial Fibrillation & Bleeding Risk

Validated stroke-risk tools, such as CHA₂DS₂-VASc, help estimate thromboembolic risk in patients with atrial fibrillation. Bleeding-risk scores, such as HAS-BLED, are intended to identify potentially modifiable bleeding risks and determine the need for closer follow-up. Current AF guidance states that bleeding-risk scores should not be used in isolation to determine eligibility for anticoagulation. They should be used to identify modifiable bleeding risks and guide closer follow-up. Stroke-prevention decisions are based primarily on estimated annual thromboembolic risk and shared decision-making.

For most patients with nonvalvular atrial fibrillation, direct oral anticoagulants (DOACs) are preferred over warfarin. Important exceptions include patients with mechanical heart valves or moderate-to-severe rheumatic mitral stenosis.

Warfarin Management

Warfarin dose adjustments should consider the patient's target INR, degree of INR elevation or reduction, indication for anticoagulation, bleeding symptoms, recent INR stability, missed doses, medication interactions, dietary changes, alcohol use, and acute illness. Adjusting the total weekly dose by a percentage can be a useful strategy for mildly out-of-range INRs, but a single 10–15% adjustment rule does not apply to every clinical situation.

INR targets for patients with mechanical heart valves vary according to the valve type, valve position, and individual thromboembolic risk factors. A single INR range should not be applied to all patients with mechanical valves.

DOAC Dosing & Periprocedural Management

Apixaban dosing should follow the current FDA labeling and indication-specific recommendations. For patients with nonvalvular atrial fibrillation, dose reduction is based on specific clinical criteria rather than reduced kidney function alone. Clinicians should confirm the appropriate dose using the patient's indication, age, body weight, serum creatinine, renal function, and current prescribing information.

Apixaban dosing should follow the current FDA labeling and the indication being treated. For patients with nonvalvular atrial fibrillation, the standard dose is 5 mg twice daily. Dose reduction to 2.5 mg twice daily is recommended only when the patient meets at least two of the following criteria:

  • Age 80 years or older

  • Body weight 60 kg (132 lb) or less

  • Serum creatinine 1.5 mg/dL or higher

Dose reduction should not be based solely on a decline in eGFR or kidney function. Other indications for apixaban and patients with more advanced kidney disease require individualized dosing based on current prescribing information.

The timing of DOAC interruption and resumption before a procedure should be individualized based on the specific anticoagulant, renal function, procedural bleeding risk, and current guideline recommendations. Some minor dental procedures may not require complete interruption, whereas higher-risk procedures often require a longer hold and a structured plan for safely restarting anticoagulation.

Resources in this episode:

If you liked this post, also check out: 

FAQs

Continue Your Learning

The Hypertension Management in Primary Care Course is part of the Real World NP Chronic Care Series, a comprehensive continuing education program designed specifically for nurse practitioners. Through case-based learning and practical clinical frameworks, you'll learn how to confidently diagnose, evaluate, and manage hypertension using current evidence and guideline-based recommendations.

The course has been peer-reviewed by hypertension specialists to help ensure the content reflects current best practices while remaining practical for everyday primary care.

Explore the Hypertension Course →

Snag our favorite, time-saving, evidence-based resources to help you take the best care of your patients (while keeping your sanity). PLUS you'll get helpful articles, podcasts, and YT video episodes sent to your inbox every week or so.

© 2026 Real World NP. For educational and informational purposes only, see realworldnp.com/disclaimer for full details.

Previous
Previous

How to Use the PREVENT Calculator

Next
Next

Ask A Cardiology Nurse Practitioner: Common Primary Care Questions Answered